tolterodine tartrate tablet, film coated
greenstone llc - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 1 mg - tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. tolterodine tartrate tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate is also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate, are metabolized to 5-hydroxymethyl tolterodine.
tolterodine tartrate- tolterodine tartrate tablet, film coated
teva pharmaceuticals usa inc - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 1 mg - tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. tolterodine tartrate tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate is also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate, are metabolized to 5- hydroxymethyl tolterodine.
tolterodine tartrate- tolterodine capsule, extended release
torrent pharmaceuticals limited - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies ( 14)]. tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [ see warnings and precautions ( 5.2), ( 5.3), ( 5.4) ] . risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal
tolterodine tartrate- tolterodine capsule, extended release
major pharmaceuticals - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies ( 14)]. tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [ see warnings and precautions ( 5.2), ( 5.3), ( 5.4) ] . risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal
tolterodine tartrate- tolterodine capsule, extended release
american health packaging - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ]. tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2), (5.3), (5.4) ]. risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal reproduction studies, oral administration of tolterodine and its 5-hmt metabolite to pregnant mice during organogenesis di
tolterodine tartrate- tolterodine tartrate capsule, extended release
teva pharmaceuticals usa inc - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ] . tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2) (5.3), (5.4) ]. risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal reproduction studies, oral administration of tolterodine and its 5-hmt metabolite to pregnant mice during organogenesis did not produce adverse deve
tolterodine tartrate extended release- tolterodine tartrate capsule, extended release
greenstone llc - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ]. tolterodine tartrate extended- release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended- release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended- release capsules , are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2) (5.3) , (5.4) ]. risk summary there are no available data with tolterodine tartrate extended- release capsules use in pregnant women to inform drug-associated risks. in animal reproduction studies, oral administration of tolterodine and its 5-hmt metabolite to pregnant mice during organogenesis did not produce adverse
tolterodine tartrate capsule, extended release
camber pharmaceuticals, inc. - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14)]. tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which , like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2)(5.3), (5.4) ]. pregnancy category c. at approximately 9 to 12 times the clinical exposure to the pharmacologically active components of tolterodine tartrate extended-release capsules, no anomalies or malformations were observed in mice (based on the auc of tolterodine and its 5-hmt metabolite at a dose of 20 mg/kg/d
deterodine sr 4 milligram prolonged release capsules
mcdermott laboratories ltd t/a gerard laboratories - tolterodine tartrate - prolonged release capsules - 4 milligram - drugs for urinary frequency and incontinence
deterodine sr 2 milligram prolonged release capsules
mcdermott laboratories ltd t/a gerard laboratories - tolterodine tartrate - prolonged release capsules - 2 milligram